Despite Slow Uptake, Excitement For and Anticipated Use of AMAG’s New IV Iron Product Feraheme (ferumoxytol) is High
UCB’s Cimzia Narrows the Gap on Centocor’s Simponi According to A Newly Released Report by BioTrends Research Group.
New Reports by BioTrends Research Group To Highlight The Launch of Novartis’ EXTAVIA® (interferon beta-1b) for Multiple Sclerosis in the US
BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year
Nephrologists Indicate High Interest in AMAG Pharmaceuticals’ Newly Approved Feraheme According to Latest BioTrends Report
Read more...
Page 9 of 17
